GENERIC-M-ENG-min
VAGINAL-GEL-M-ENG-min
EXT-GEL-M-ENG-min
INMUNOCAPS-M-ENG-min
Previous
Next
GENERIC-ENG-min
VAGINAL-GEL-ENG-min
EXTERNAL-GEL-ENG-min
INMUNOCAPS-ENG-min

Rest Assured.

There is already a solution for HPV

We finally have an effective treatment specifically designed to prevent and treat lesions* caused by the human papillomavirus (HPV): the Papilocare® family.

A line of therapeutic products composed of bio-optimized ingredients of natural origin, capable of balancing the vaginal microbiota, facilitating the re-epithelialization of lesions and improving genital health

Its different presentations also allow a thorough function, both locally and systemically**, which translates into a clinically proven efficacy of up to 90%: the vast majority of people who use Papilocare® treatment manage to normalize the lesions and get negative results on the high-risk HPV test in an average period of between three and six months, without any kind of side effects

This data provides a great sense of comfort and justified optimism to every woman who has received a positive HPV test

*Low-grade cervical lesions (ASCUS/LSIL) and genital warts

**Effect achieved with the use of Papilocare® Inmunocaps food supplement

Stand up to HPV with Papilocare®

Clinical development plan

Commitment to research

Research and scientific support are in our DNA. For this reason, we constantly strive to validate and demonstrate the efficacy of our treatments, through different national and international clinical trials

In fact, the effectiveness of Papilocare® has been confirmed in 6 different trials, where the evolution of more than 700 patients have been constantly studied, among which the Paloma clinical trial stands out, the results of which have been published in the Journal of Lower Genital Tract Diseases, one of the most prestigious medical journals in the area of gynecology

The data that has been collected until this day allows us to firmly state that Papilocare® vaginal gel normalizes lesions in nine out of ten patients and gets negative results on the high-risk HPV test in 63% of cases, with only six months of treatment.

See the interview Dr. Javier Cortés

Medical

recognition

We have a strong presence in the main national and international congresses of the field and especially in those of cervical pathologies

Nearly 100 accepted abstracts, oral presentations, symposiums and publications

Social

recognition

2021’s Product of the year

Best treatment against HPV in the IV Edition of the Valencian Community Awards given by La Razón

Internacionalization

Our goal is that all patients, regardless of who they are or where they live, can have access to an effective treatment to heal and overcome the lesions caused by HPV. For this reason, since the launch of the Papilocare® family in 2016, we have strengthened and consolidated our international presence in different parts of the planet. And we will continue to do so to reach even further

Currently, the treatment can be found on four continents and in nearly 60 countries, including its recent entry into the Chinese market

Papilocare in the world

Meet Procare Health

Papilocare® is part of the extensive range of health products from Procare Health, a pioneering Spanish pharmaceutical laboratory dedicated entirely to the development of bio-optimized and scientifically proven natural solutions for women’s health and well-being.

Its varied portfolio of products covers all the physiological stages of a woman’s life and ranges from reproductive health to advanced menopause.

Meet Procare Health

Papilocare® News

Stay up to date and don't miss any news about Papilocare® and their advances in the study of the human papillomavirus